New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2013
10:02 EDTVIPS, LXP, DRRX, EROC, SFLY, RRD, CEB, BRS, CNDO, GALE, CMCSAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bristow Group (BRS) initiated with an Overweight at JPMorgan... Comcast (CMCSA) reinstated with a Buy at Goldman... Coronado Biosciences (CNDO) initiated with a Buy at Canaccord... Corporate Executive Board (CEB) initiated with a Buy at SunTrust... Eagle Rock Energy (EROC) coverage resumed with a Market Perform at Wells Fargo... Galena Biopharma (GALE) initiated with a Buy at Needham... Lexington Realty (LXP) initiated with a Hold at KeyBanc... Rentech Nitrogen (RNF) initiated with a Neutral at Goldman... R.R. Donnelley (RRD) initiated with a Buy at Sidoti... Durect (DRRX) initiated with a Buy at Stifel... Vipshop (VIPS) initiated with an Overweight at JPMorgan... Shutterfly (SFLY) initiated with a Buy at Needham... Coronado Biosciences (CNDO) initiated with a Buy at Canaccord.
News For BRS;CMCSA;CNDO;CEB;GALE;EROC;LXP;RRD;DRRX;VIPS;SFLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 20, 2015
10:30 EDTVIPSOptions with decreasing implied volatility
Subscribe for More Information
07:18 EDTCMCSAComcast volatility elevated into Q4 and outlook
Subscribe for More Information
06:49 EDTCMCSAMSNBC cancels two talk shows, Politico says
Subscribe for More Information
06:24 EDTCEBCorporate Executive Board management to meet with William Blair
Subscribe for More Information
February 19, 2015
07:36 EDTLXPLexington Realty sees FY15 FFO $1.00-$1.05, consensus $1.08
07:36 EDTLXPLexington Realty reports Q4 FFO 27c, consensus 27c
Subscribe for More Information
07:30 EDTCMCSANBC 'Nightly News' sees drop in ratings post-Brian Williams, WSJ says
Subscribe for More Information
February 18, 2015
08:38 EDTCNDOCoronado in-licenses IV Tramadol from Revogenex Ireland
Coronado Biosciences has obtained an exclusive license to an intravenous formulation of tramadol for the U.S. market from Revogenex Ireland, a privately held company in Dublin, Ireland. Coronado has formed a wholly owned subsidiary, Avenue Therapeutics, Inc., to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. Coronado will transfer the Revogenex license to Avenue Therapeutics, Inc. In addition to IV tramadol, Avenue Therapeutics plans to seek additional products. Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets in the U.S. It has been reported that oral tramadol sales were approximately $1.2B in the U.S. in 2014.
07:55 EDTVIPSVipshop results show increased market penetration, says Brean Capital
Subscribe for More Information
07:13 EDTCMCSANational Association of Regulatory Utility Commission to hold a meeting
Subscribe for More Information
06:33 EDTCMCSAJAKKS Pacific signs licensing agreement for Universal Pictures franchise
Subscribe for More Information
February 17, 2015
12:56 EDTCMCSADecline of TV viewing accelerated, NY Post reports
Subscribe for More Information
12:14 EDTVIPSVipshop price target raised to $30 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTVIPSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Vipshop Holdings (VIPS), up 10.9%... VASCO Data Security (VDSI), up 7.1%... Waste Management (WM), up 3.7%. ALSO HIGHER: Starwood Hotels (HOT), up 1.9% after appointing Adam Aron as interim CEO... Sarepta Therapeutics (SRPT), up 7.3% after being upgraded at BofA/Merrill... Navidea Biopharmaceuticals (NAVB), up 7.5% after publishing results of phase 3 Lymphoseek trial... Campus Crest (CCG), up 7.7% after announcing that it will explore strategic alternatives as well as Clinton Group and Campus Evolution proxy contest... Cyren (CYRN), up 7.1% following distribution agreement with ALSO Deutschland. DOWN AFTER EARNINGS: Helix Energy (HLX), down 13.3%... Walter Energy (WLT), down 10.1%. ALSO LOWER: Celsus Therapeutics (CLTX), down 82.3% after MRX-6 Cream 2% Phase II trial did not meet primary endpoint... Vascular Biogenics (VBLT), down 53.2% after reporting that VB-201 Phase 2 studies did not meet primary endpoints and removal of FDA partial clinical hold on VB-111... Vanguard Natural Resources (VNR), down 7.1% after reporting preliminary fourth quarter results.
07:15 EDTCMCSA'Fifty Shades' opens to $94.4M, WSJ says
Comcast (CMCSA, CMCSK) subsidiary Universal's "Fifty Shades of Grey" earned roughly $94.4M in its opening weekend, reports the Wall Street Journal. The film earned an additional $172M overseas. Fox' (FOX, FOX.A) "Kingsman: The Secret Service" debuted in second place with $42M, and Viacom (VIA, VIA.B) subsidiary Paramount's "SpongeBob SquarePants: Sponge Out of Water" took $40M in its second week. Reference Link
06:35 EDTRRDR.R. Donnelley awarded multi-year contract by Sterling Publishing
Subscribe for More Information
04:57 EDTVIPSVipshop volatility elevated at 66 into O4 and outlook
Subscribe for More Information
February 16, 2015
19:13 EDTCMCSALiberty Global may become takeover target, NY Times says
Subscribe for More Information
16:09 EDTVIPSVipshop sees Q1 revenue $1.25B-$1.30B, consensus $1.22B
Subscribe for More Information
16:08 EDTVIPSVipshop reports Q4 EPS 12c, consensus 9c
Reprots Q4 revenue $1.36B, consensus $1.23B. Results are unaudited. Gross margin increased to 24.9% from 24.5% last year. The number of active customers for Q4 increased by 114.2% to 12.2M from 5.7M in the prior year period. The number of total orders for Q4 increased by 99.6% to 35.3M from 17.7M in the prior year period. Vipshop said, "This increase was primarily due to increased brand recognition, as well as the Company's continued efforts in optimizing and diversifying brand and product selection available on both PC and mobile platforms."
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use